Trial · NCT02154347
Adverse events105
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 105
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Cold sweat | Skin and subcutaneous tissue disorders | Placebo/KAD-1229 (Data Through Week 16) | 0 | 60 | |
| other | Cold sweat | Skin and subcutaneous tissue disorders | KAD-1229/KAD-1229 (Data Through Week 16) | 2 | 118 | |
| other | Cold sweat | Skin and subcutaneous tissue disorders | KAD-1229 (Data Through Week 52) | 9 | 175 | |
| other | Hunger | General disorders | Placebo/KAD-1229 (Data Through Week 16) | 1 | 60 | |
| other | Hunger | General disorders | KAD-1229/KAD-1229 (Data Through Week 16) | 2 | 118 | |
| other | Hunger | General disorders | KAD-1229 (Data Through Week 52) | 9 | 175 | |
| other | Asthenia | General disorders | Placebo/KAD-1229 (Data Through Week 16) | 2 | 60 | |
| other | Asthenia | General disorders | KAD-1229/KAD-1229 (Data Through Week 16) | 2 | 118 | |
| other | Asthenia | General disorders | KAD-1229 (Data Through Week 52) | 8 | 175 | |
| other | Dizziness | Nervous system disorders | Placebo/KAD-1229 (Data Through Week 16) | 1 | 60 | |
| other | Dizziness | Nervous system disorders | KAD-1229/KAD-1229 (Data Through Week 16) | 3 | 118 | |
| other | Dizziness | Nervous system disorders | KAD-1229 (Data Through Week 52) | 8 | 175 | |
| other | Hypoglycaemia | Metabolism and nutrition disorders | Placebo/KAD-1229 (Data Through Week 16) | 2 | 60 | |
| other | Hypoglycaemia | Metabolism and nutrition disorders | KAD-1229/KAD-1229 (Data Through Week 16) | 1 | 118 | |
| other | Hypoglycaemia | Metabolism and nutrition disorders | KAD-1229 (Data Through Week 52) | 6 | 175 | |
| other | Palpitations | Cardiac disorders | Placebo/KAD-1229 (Data Through Week 16) | 0 | 60 | |
| other | Palpitations | Cardiac disorders | KAD-1229/KAD-1229 (Data Through Week 16) | 2 | 118 | |
| other | Palpitations | Cardiac disorders | KAD-1229 (Data Through Week 52) | 6 | 175 | |
| other | Nasopharyngitis | Infections and infestations | Placebo/KAD-1229 (Data Through Week 16) | 10 | 60 | |
| other | Nasopharyngitis | Infections and infestations | KAD-1229/KAD-1229 (Data Through Week 16) | 13 | 118 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02154347/events